PHOENIX, A.Z., (August 21, 2020) Kalos Therapeutics today announced positive preclinical efficacy results from a series of Kalos peptides for the treatment of COVID-19. Continue reading
The launch will help campus reopen while also serving as a pilot for the state of Arizona.Continue reading
TUCSON, Ariz., Aug. 18, 2020 /PRNewswire/ — Accelerate Diagnostics, Inc. (NASDAQ: AXDX) and BioCheck, Inc., a privately-held San Francisco-based company focused on in vitro diagnostics, today announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the BioCheck SARS-CoV-2 IgM and IgG Combo Test and fully-automated MS-Fast instrument.Continue reading
FDA, August 15, 2020: Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) to Yale School of Public Health for its SalivaDirect COVID-19 diagnostic test, which uses a new method of processing saliva samples when testing for COVID-19 infection.Continue reading
Labs and art studios will be among the first courses to take place in person, while other classes will begin online on Aug. 24.
The Center for Applied NanoBioscience and Medicine Awarded Grant from NASA to Develop Prototype by September 2020
Amid the coronavirus pandemic, a team of researchers at the University of Arizona College of Medicine – Phoenix are developing a device that will easily and accurately detect COVID-19 in a matter of minutes.Continue reading
Company working to ensure broad global access to COVID-19 vaccine candidate, following approval from regulatorsContinue reading
AdvaMed’s National Testing Registry: Shipments of COVID-19 Molecular Diagnostic Tests Reach 100 MillionContinue reading
- Promising vaccine candidate selected by U.S. government’s Operation Warp Speed
- U.S. government to provide funding up to $2.1 billion for development including clinical trials, manufacturing, scale-up and delivery of an initial 100 million doses
- Ongoing discussions with European Commission – with France and Italy on the negotiation team – and other governments to ensure global access to a novel coronavirus vaccine
- Sanofi and GSK today announce a collaborative effort with the U.S. government to accelerate the development and manufacturing of a COVID-19 recombinant protein-based vaccine.
Thanks to a U.S. Department of Defense contract for as much as $9.5 million, the University of Arizona College of Medicine – Phoenix and partners aim to develop a portable device to easily and accurately detect biological threats, including the virus that causes COVID-19.Continue reading